Breeding of Animal Models
Maintenance of Established and Newly Developed Rodent Models:
- Transgenics
- Knockout
- Conditional/inducible models
- Multiple mutations
Colony Management:
- Breeder set-up/take down
- Weaning, identification, DNA sampling
- In-house genotyping
- Import/export coordination
Data Management:
- Precise recordkeeping
- Generation tracking
- Custom electronic inventories /databases
Custom Breeding Protocols Tailored to Need:
- Continual supply or peak breeding
- Conventional backcrossing to inbred background
- Cre-lox breeding
Specialized Breeding Husbandry:
- Timed matings
- Caesarean rescue
- Cross-fostering
- Troubleshooting breeding performance
AAALAC- Accredited Facilities:
- Specific-Pathogen Free and Conventional Facility housing options
- Short or long-term space to house and breed research animal colonies
- ILS Health Monitoring Program
Lead Scientist
Glenda Moser, Ph.D. DABT
Dr. Moser has over 20 years of experience in in vivo and in vitro studies. She has managed and successfully supervised studies evaluating gene and protein expression as early endpoint predictors of phenotypic alterations. Dr. Moser is responsible for the development of Standard Operating Procedures (SOPs) and the quality control and training programs in the toxicology division. She is responsible for compliance to pertinent policies, rules and regulations for the AAALAC, PHS policy, Animal Welfare Act, and United States Department of Agriculture (USDA). She has conducted in vivo studies under Good Laboratory Practices, Guidelines for submission to the EPA, FDA, and Organisation for Economic Co-operation and Development (OECD). She also responds to the ILS and NIEHS IACUCs. Dr. Moser has extensive experience in designing, implementing, and managing research studies, conducting statistical analysis, and writing protocols, and manuscripts. Dr. Moser received both her M.S. and Ph.D. in Toxicology and Pharmacology from North Carolina State University where she published seven manuscripts describing the mechanisms of mirex-induced skin tumors with mutations in the Ha-ras gene and the toxicant-induced disruption of signal transduction pathways.